Drug Database
Back to search

Belgium· BE-AMP-SAM292616-00

Inovelon 400 mg

A rufinamide product containing rufinamide, registered in Belgium by Eisai. The same ATC class is registered in 17 of our 19 countries.

ATC N03AF03

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedInovelon 400 mgATCN03AF03REGISTER NO.BE-AMP-SAM292616-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about rufinamideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Rufinamide is registered in 17 of 19 countries.

Countries holding a registration under ATC N03AF03 (rufinamide), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 10 of them publish a price we can compare per daily dose
Search rufinamide products by name

Rufinamide · ATC N03AF03

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rufinamide costs, country by country.

Normalised to the WHO defined daily dose (1.4 g), the median price runs from $7.83 in Switzerland to $12.24 in Italy — a ×1.6 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Rufinamide · price per daily dose (1.4 g)

USD · FX 28 Sept 2026

  • IT Italy$12.24
  • FR France$8.57
  • CH Switzerland$7.83
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Rufinamide
Manufacturer
Eisai
Country
Belgium (BE)
ATC code
N03AF03
ATC class
Rufinamide
Defined daily dose
1.4 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    0754051
  • be_apb
    2695906

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

238 interactions on record for rufinamide.

Graded by severity as the source publishes them — 232 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check rufinamide against other medicinesHow interaction checks work

Rufinamide · interactions on record

238 records

  • 232 moderate
  • 6 minor

Most severe, free to view

  • MetoclopramideA03FA01moderate
  • OndansetronA04AA01moderate
  • GranisetronA04AA02moderate
  • ThiethylperazinA04AB03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rufinamide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rufinamide products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

  • Germany · Rufinamid Actrevo, Rufinamid Micro Labs
  • France · Rufinamide Actrevo, Rufinamide Medipha
  • United Kingdom (Northern Ireland) · Rufinamide, Rufinamide Brown & Burk
  • Iceland · Inovelon
  • Liechtenstein · Inovelon
  • Norway · Inovelon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0d837fa1-5b9c-4b42-add2-23a6d09f716a
GET /v1/drugs/0d837fa1-5b9c-4b42-add2-23a6d09f716a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Inovelon 400 mg",
  "name_fr": "Inovelon 400 mg",
  "name_nl": "Inovelon 400 mg",
  "amp_code": "SAM292616-00",
  "strengths": [
    "400.0000"
  ],
  "pack_count": 6,
  "substances": [
    "Rufinamide",
    "Sodium Laurilsulfate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Rufinamide",
  "authorisation_numbers": [
    "EU/1/06/378/011",
    "EU/1/06/378/012",
    "EU/1/06/378/013",
    "EU/1/06/378/014",
    "EU/1/06/378/015",
    "EU/1/06/378/016"
  ]
}
API referenceMCP serverPlans

See everything about rufinamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console